Javier Rodriguez - 22 Jul 2024 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Legal Officer, Senior Vice President and Corporate Secretary
Signature
/s/ Richard Steinhart, Attorney-in-Fact for Javier Rodriguez
Issuer symbol
BTAI
Transactions as of
22 Jul 2024
Net transactions value
$0
Form type
4
Filing time
01 Apr 2025, 18:04:24 UTC
Previous filing
18 Jun 2024
Next filing
17 Sep 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTAI Restricted Stock Units Award $0 +625 $0.000000 625 22 Jul 2024 Common Stock 625 Direct F1, F2, F3
transaction BTAI Stock Option (right to buy) Award $0 +1,875 $0.000000 1,875 22 Jul 2024 Common Stock 1,875 $1.20 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The share amount has been adjusted to reflect the reverse stock split effective on February 7, 2025 whereby every sixteen shares issued and outstanding prior to the split were combined and converted into one share of common stock.
F3 The RSUs will vest and settle as to 100% of the total number of RSUs on the first anniversary of the grant date, subject to the Reporting Person's continuous employment with the Issuer through such date.
F4 The Reporting Person was granted an option to purchase 1,875 shares of common stock, which vests as to 50% on each of the first and second anniversaries of the grant date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.

Remarks:

Chief Legal Officer, Senior Vice President and Corporate Secretary